Journal of clinical virology plus最新文献

{"title":"“Systematic review of HHV-6 and febrile seizures: Should the ER include it in the viral panel?”","authors":"Valerie Foy ,&nbsp;Shaina Gagadam","doi":"10.1016/j.jcvp.2025.100233","DOIUrl":"10.1016/j.jcvp.2025.100233","url":null,"abstract":"<div><h3>Background</h3><div>Human herpesvirus 6 (HHV-6), particularly subtype B, is a common viral infection in childhood and the cause of roseola infantum. Beyond its dermatologic effects, HHV-6B is an important yet often underrecognized contributor to febrile seizures in young children presenting to the emergency department (ED).</div></div><div><h3>Objective</h3><div>This systematic review aims to examine the virology, epidemiology, and clinical features of HHV-6 infection in children, focusing on neurologic manifestations, while evaluating current ED diagnostic practices and the potential role for HHV-6 testing in pediatric febrile seizures.</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines, a comprehensive search of PubMed and Embase databases identified studies published up to September 2025 on HHV-6 virology, dermatologic findings, neurologic complications, and ED management in pediatric patients. Inclusion criteria focused on HHV-6′s role in febrile seizures and the utility of rapid molecular diagnostics in the ED. Search terms included keywords related to HHV-6, febrile seizures, and pediatric emergency care. Two reviewers independently performed full-text reviews and extracted data.</div></div><div><h3>Results</h3><div>Primary HHV-6B infection affects most children by age two, with up to 30 % of first febrile seizures in this group attributed to the virus. While mostly self-limited, HHV-6B is disproportionately associated with complex febrile seizures and febrile status epilepticus. Emerging rapid diagnostic tools offer opportunities for targeted testing in select high-risk populations but are costly.</div></div><div><h3>Conclusions</h3><div>HHV-6B is an underrecognized cause of febrile seizures in pediatrics. Selective screening for complex or prolonged seizures may enhance improve long-term outcomes. Until stronger evidence emerges, clinicians should interpret HHV-6B results within the broader clinical context.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100233"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145519939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of dried blood spot vs. venous sample collection on SARS-CoV-2 antibody test results in the CLSA serological study of older Canadians","authors":"Jiacheng Chen ,&nbsp;Yuan Yu ,&nbsp;Steven J. Drews ,&nbsp;W. Alton Russell","doi":"10.1016/j.jcvp.2025.100236","DOIUrl":"10.1016/j.jcvp.2025.100236","url":null,"abstract":"<div><h3>Background</h3><div>Participant-collected dried blood spots (DBS), which can be returned using regular mail, are convenient for collecting samples for population serology studies. The impact of DBS sampling on assay performance remains unclear.</div></div><div><h3>Objective</h3><div>We estimated the impact of using DBS samples on estimates of population SARS-CoV-2 antibody levels within a study of older Canadians.</div></div><div><h3>Study Design</h3><div>Analyzing data from 3 796 participants who provided DBS samples and 3 457 participants who provided venous samples, we estimated the impact of sample collection modality on odds of testing positive for anti-nucleocapsid antibodies (Anti-N) or for antibodies to the SARS-CoV-2 spike protein (Anti-S) using the Elecsys Anti-SARS-CoV-2 and Anti-SARS-CoV-2 S immunoassays. We used inverse probability of treatment weighting to control for differences between participants who provided DBS or venous samples, including sample collection date and participants’ age, vaccination status, and geographic location.</div></div><div><h3>Results</h3><div>Compared to venous samples, DBS samples were less likely to be Anti-N positive (weighted risk ratio [RR]: 0.30, 95 % confidence interval [CI]: 0.25–0.36) and less likely to be Anti-S positive (RR: 0.83, 95 % CI: 0.80–0.86). We estimate that using DBS for all participants would have underestimated seropositivity for anti-N antibodies (2.48 % using DBS; 8.32 % using venous) and anti-S antibodies (42.7 % using DBS; 51.6 % using venous).</div></div><div><h3>Discussion</h3><div>In population serology studies, DBS samples should only be used instead of venous blood draws when the impact on assay performance is well-characterized and appropriate adjustments are used to derive population seropositivity estimates.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100236"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145684125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic reactogenicity is a correlate of MF59 adjuvant-moderated immunogenicity in influenza vaccinated children","authors":"Charlotte Switzer ,&nbsp;Chris P. Verschoor ,&nbsp;Eleanor Pullenayegum ,&nbsp;Pardeep Singh ,&nbsp;Mark Loeb","doi":"10.1016/j.jcvp.2025.100234","DOIUrl":"10.1016/j.jcvp.2025.100234","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvanted influenza vaccine induces more robust antibody responses, but is associated with more adverse events following vaccination. Prior work has examined the link between vaccine reactions and immunogenicity in adults, but little is known about the association between reactogenicity and postvaccination antibody responses in children, particularly regarding adjuvanted influenza vaccine. This study examines the relationship between reactogenicity and immunogenicity in children vaccinated against influenza, and the immunomodulatory effects of the adjuvant.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis of data from a cluster-randomized trial of children aged 6 to 72 months from Canadian Hutterite colonies. Participants received either a trivalent MF59-adjuvanted vaccine (aTIV) or a quadrivalent non-adjuvanted vaccine (QIV). Reactogenicity was measured using a composite score based on local, systemic, and respiratory reactions recorded within five days post-vaccination. Immunogenicity was assessed by measuring hemagglutination inhibition (HAI) titers before and four weeks after vaccination. Linear mixed models were used to evaluate associations between reactogenicity scores and post-vaccination log-transformed HAI titers.</div></div><div><h3>Results</h3><div>In adjuvanted vaccinees, higher systemic reactogenicity scores were associated with increased antibody titers for A/H1N1 and B/Victoria, relative to nonadjuvanted vaccinees (β: 0.38, 95 % CI: 0.17 to 0.60; and (β: 0.44, 95 % CI: 0.24 to 0.64 respectively). Higher systemic reactogenicity in nonadjuvanted vaccinees correlated with reduced post-vaccination antibody titers for A/H1N1 (β:0.36, 95 % CI:0.54 to -0.18) and B/Victoria (β:0.37, 95 % CI:0.54 to -0.20). Respiratory reactogenicity was positively correlated with immunogenicity in responses to A/H3N2 in the adjuvanted group (β: 0.78, 95 % CI: 0.13 to 1.43). Local reactogenicity was associated with A/H1N1 immunogenicity, but showed no significant interaction with vaccine formulation (β: 0.25, 95 % CI: 0.04 to 0.47).</div></div><div><h3>Conclusions</h3><div>Systemic reactogenicity in adjuvanted vaccinees showed positive correlations with immunogenicity, whereas reactogenicity contributed to blunting of antibody responses in nonadjuvanted vaccinees. We found that stronger systemic reactions correlate with improved immune responses in the adjuvanted group against all vaccine strains save A/H3N2, which warrants further investigation. Our study finds that reactogenicity is a modest biomarker for vaccine immunogenicity, and that the increased reactogenicity of the adjuvanted vaccine is associated with enhanced immune responsiveness, which may predict greater vaccine effectiveness.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100234"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The immunogenicity of recombinant zoster vaccination in patients with secondary immunodeficiencies: a literature review","authors":"Stascha I. Kuipers ,&nbsp;Marjolein Knoester ,&nbsp;Carin L.E. Hazenberg ,&nbsp;Debbie van Baarle ,&nbsp;Marieke van der Heiden","doi":"10.1016/j.jcvp.2025.100231","DOIUrl":"10.1016/j.jcvp.2025.100231","url":null,"abstract":"<div><div>Herpes zoster (HZ), caused by reactivation of the varicella zoster virus, is characterized by painful rashes and severe complications. Immunocompromised individuals are at greater risk of developing HZ. Vaccination with the novel recombinant adjuvanted zoster subunit vaccine (RZV) proved highly effective in older adults and is considered safe in patients with secondary immunodeficiencies. This review summarizes the current evidence on efficacy and immunogenicity of RZV in patients with secondary immunodeficiencies and identifies factors associated with reduced immunogenicity.</div><div>RZV is highly immunogenic in patients with HIV and most haematological malignancies. Reduced responsiveness has been observed in patients with solid tumours, chronic lymphocytic leukaemia, non-Hodgkin B-cell lymphoma, autologous haematopoietic cell transplants, and solid organ transplants. Reduced response is associated with Rituximab and post-transplantation immunosuppressive treatments, as well as immunosuppressive effects of solid tumours and chemotherapy. Future research should investigate whether personalised vaccination schedules, guided by biomarkers for immune function and treatment and/or transplantation schedules, may improve RZV responsiveness.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100231"},"PeriodicalIF":1.4,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145266557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of dried blood spot sampling in quantifying hepatitis B DNA in Vietnam","authors":"Manh-Tuan Ha ,&nbsp;Duyen Thi-My Nguyen ,&nbsp;Tuan-Anh Nguyen","doi":"10.1016/j.jcvp.2025.100230","DOIUrl":"10.1016/j.jcvp.2025.100230","url":null,"abstract":"<div><h3>Background</h3><div>Sampling is a crucial step in quantifying HBV DNA. In some situations, dried blood spot (DBS) sampling is required. This study aimed to validate the accuracy of HBV DNA quantification from DBS samples and to evaluate the stability of HBV DNA levels under practical storage conditions.</div></div><div><h3>Materials and Methods</h3><div>We collected paired serum and DBS samples from HBV DNA-positive cases and HBV DNA-negative controls (1:1 ratio). The validity of DBS samples in HBV DNA quantification was determined using serum results as a gold standard.</div></div><div><h3>Results</h3><div>The study analyzed 100 paired DBS and serum samples from both cases and controls. It reported relatively high sensitivity (86.7%) and specificity (97.6%) for DBS samples in detecting HBV DNA levels greater than 2000 IU/mL. A strong linear regression correlation was found between HBV DNA levels in DBS and serum samples, with an R² of 0.8679 (p &lt; 0.001) and the regression equation y = 0.9095x - 0.7792. The mean difference in HBV DNA levels between DBS and serum was 1.28 ± 0.78 log10 IU/mL. Notably, differences in HBV DNA levels in DBS samples remained insignificant after 14 days of storage at both 4°C and room temperature (p&gt;0.05), indicating stability under various storage conditions.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that DBS samples are effective for identifying patients eligible for treatment and remain stable at room temperature for at least 14 days, supporting their feasibility in real-world settings. The use of DBS samples for monitoring hepatitis B treatment response and optimizing the elution process presents promising research opportunities.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100230"},"PeriodicalIF":1.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145266558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of inflammatory markers including neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, platelet distribution width, and red blood cell distribution width in viral hepatitis: A systematic review and meta-analysis","authors":"Peyvand Parhizkar Roudsari ,&nbsp;Shayan Shojaei ,&nbsp;Parisa Firoozbakhsh ,&nbsp;Alireza Azarboo ,&nbsp;Saeed Mirmoosavi ,&nbsp;Ali Moradi ,&nbsp;Faeze Abbaspour ,&nbsp;Asma Mousavi ,&nbsp;Hanieh Radkhah","doi":"10.1016/j.jcvp.2025.100229","DOIUrl":"10.1016/j.jcvp.2025.100229","url":null,"abstract":"<div><h3>Background</h3><div>Hematological markers offer valuable and cost-effective tools for hepatitis prognosis and treatment customization due to their role in inflammatory responses. Hence, this study seeks to explore the prognostic potential of inflammatory markers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet distribution width (PDW), and red blood cell distribution width (RDW) in viral hepatitis patients.</div></div><div><h3>Methods</h3><div>We conducted a systematic search in online databases of PubMed, Web of Science, Scopus, and Cochrane for related articles following PRISMA guidelines. Our endpoint was to evaluate the association between NLR, PLR, MPV, PDW, and RDW with fibrosis and cirrhosis outcomes in patients with hepatitis B and C. The analysis used the \"meta\" package in R, employing Hedges' g to calculate the standardized mean difference (SMD) and 95 % confidence intervals (CI). A P value less than 0.05 was considered statistically significant for all data analyses</div></div><div><h3>Results</h3><div>Thirty-seven studies were ultimately included in the analysis. PLR was higher in mild fibrosis (SMD = -0.48, 95 % CI: -0.90; -0.06), with no significant differences observed by hepatitis type. Both MPV and RDW were higher in advanced fibrosis (MPV: SMD = 0.36, 95 % CI: 0.19; 0.53, RDW: SMD = 0.32, 95 % CI: 0.14; 0.50), and they were significantly increased in advanced hepatitis C fibrosis. PDW was higher in advanced fibrosis (SMD = 0.32, 95 % CI: 0.02; 0.61), significantly in hepatitis B. In cirrhotic versus non-cirrhotic patients, MPV (SMD = 0.22, 95 % CI: 0.07; 0.38) and RDW (SMD = 1.35, 95 % CI: 0.62; 2.08) were higher in the cirrhotic group, while PLR (SMD = -1.15, 95 % CI: -2.16; -0.15) was higher in the non-cirrhotic group. NLR showed no significant difference between mild and advanced fibrosis or between cirrhotic and non-cirrhotic groups.</div></div><div><h3>Conclusion</h3><div>This meta-analysis reveals the importance of hematological parameters of MPV, PDW, RDW, and PLR as predictors of viral hepatitis progression. MPV, PDW, and RDW are elevated in advanced fibrosis, while PLR is notably higher in mild fibrosis.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 4","pages":"Article 100229"},"PeriodicalIF":1.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"China reports first human case of Mpox: A call for global surveillance for public health and policy","authors":"Uthman Okikiola Adebayo ,&nbsp;Tolutope Adebimpe Oso ,&nbsp;Safayet Jamil ,&nbsp;Olalekan John Okesanya ,&nbsp;Mohamed Mustaf Ahmed","doi":"10.1016/j.jcvp.2025.100226","DOIUrl":"10.1016/j.jcvp.2025.100226","url":null,"abstract":"","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100226"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of an automated platform for CMV, EBV and BKPyV DNA detection and quantification","authors":"Yoann Fluhr ,&nbsp;Karine Saune ,&nbsp;Kevin Oliveira-Mendes ,&nbsp;Estelle Raguin ,&nbsp;Lila Poiteau ,&nbsp;Arnaud Del Bello ,&nbsp;Nassim Kamar ,&nbsp;Jacques Izopet ,&nbsp;Florence Abravanel","doi":"10.1016/j.jcvp.2025.100228","DOIUrl":"10.1016/j.jcvp.2025.100228","url":null,"abstract":"<div><div>Quantification of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and BK polyomavirus (BKPyV) DNA is crucial for diagnosing related infections. The analytical performance of the Altostar® CMV, EBV and BKPyV DNA assays used in the AltoStar® AM16 instrument was assessed.</div><div>The Limit of detection was 215 international units/ml (IU/ml) for the CMV assay, 330 IU/ml for the EBV assay and 133 IU/ml for the BKPyV assay. A good concordance was found between the nominal value of the NIBSC standards and the AltoStar® results. Linearity was verified up to 5.7 log₁₀ IU/ml. Intra-assay and inter-assay reproducibility showed low disparity with a standard deviation &lt; 0.27 log₁₀ IU/ml.</div><div>The concordance with our previous DNA assays on clinical samples for CMV detection was 95.5% (<em>n</em> = 22), 90.6% for EBV (<em>n</em> = 32) and 92% for BKV (<em>n</em> = 25). The quantitative results were highly correlated.</div><div>The Altostar® platform provides accurate quantification for clinical monitoring of CMV, EBV and BKPyV DNA.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100228"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144679836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue virus proteins: Dual drivers of pathogenesis and vaccine development","authors":"Haidar Ali ,&nbsp;Iffat Saleem ,&nbsp;Kashif Abdaal ,&nbsp;Mobeen Ur Rashid ,&nbsp;Imran Shahid ,&nbsp;Sadia Aziz ,&nbsp;Jing Yang ,&nbsp;Liaqat Ali","doi":"10.1016/j.jcvp.2025.100227","DOIUrl":"10.1016/j.jcvp.2025.100227","url":null,"abstract":"<div><div>This systematic review provides a comprehensive exploration of Dengue virus (DENV), focusing on its history, transmission dynamics, tropism, structural proteins, and potential vaccine development targets. Originating from sub-Saharan Africa, DENV has spread globally, facilitated by Aedes mosquitoes. The review highlights challenges posed by mosquito expansion and climate change on DENV transmission. It delves into DENV tropism, emphasizing interactions with immune cells and tissue-specific infection outcomes. Structural proteins, including Capsid, Pre-Membrane, and Envelope, are examined for their roles in viral assembly and maturation. Targeting strategies for structural proteins, particularly the Envelope protein domain III (EDIII), are discussed in the context of vaccine development. Additionally, non-structural proteins such as NS1, NS3, and NS5 are explored for their contributions to viral replication, host immune modulation and potential as both therapeutic targets and vaccine components. By integrating insights into both structural and non-structural elements of DENV, this review underscores the importance of a multifaceted approach to vaccine design and antiviral development aimed at effectively controlling dengue infection and its associated disease burden.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100227"},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and clinical characteristics of human bocavirus in respiratory illnesses across diverse age groups in Lagos, Nigeria","authors":"Abdul-Azeez A. Anjorin ,&nbsp;Oluwaseyi S. Ashaka ,&nbsp;Joseph Eyedo ,&nbsp;Abdulrauf O. Abdulkareem ,&nbsp;Taofeeq A. Balogun ,&nbsp;Zainab B. Salami ,&nbsp;Kabiru O. Akinyemi","doi":"10.1016/j.jcvp.2025.100225","DOIUrl":"10.1016/j.jcvp.2025.100225","url":null,"abstract":"<div><h3>Background</h3><div>Human Bocavirus (HBoV) first described by Allander and colleagues in 2005 is one of the most common viral pathogens causing respiratory diseases. It is a single-stranded DNA virus from the Parvoviridae family that is associated with respiratory and gastrointestinal infections. The prevalence and impact of the HBoV in Lagos, Nigeria, particularly across all age groups, remain underexplored.</div></div><div><h3>Aim</h3><div>This study aimed to determine the prevalence of HBoV among individuals with respiratory symptoms and its association with disease in Lagos, Nigeria.</div></div><div><h3>Methods</h3><div>A hospital-based, cross-sectional study was conducted from December 2022 to May 2023 in Lagos. Nasopharyngeal swabs were collected from 400 participants presenting with respiratory symptoms across diverse age groups. The samples were analysed for HBoV DNA using real-time PCR. Demographic and clinical data were recorded, and statistical analysis was performed using SPSS.</div></div><div><h3>Results</h3><div>The overall prevalence of HBoV was 12.5 % (57/400), with a higher 24.6 % prevalence in participants aged 21–30 years than 8.4 % in those aged ≤10 years. The participants diagnosed with respiratory disease had a significantly greater 20.3 % prevalence of HBoV compared to 8.4 % without respiratory disease (χ²=11.69, <em>p</em> = 0.0006). Fever and runny nose were the most common symptoms among HBoV-positive participants, regardless of respiratory disease status.</div></div><div><h3>Conclusions</h3><div>HBoV is prevalent in Lagos and contributes significantly to respiratory illnesses across all age groups, with the highest burden observed in young adults. These findings underscore the need for further research on the clinical implications of HBoV and its potential for nosocomial transmission in healthcare settings.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 3","pages":"Article 100225"},"PeriodicalIF":1.6,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144550047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}